VeonGen Therapeutics
Germany - PlaneggBiotechnology
Focus: VeonGen is an early-stage AAV gene therapy company focused on inherited retinal diseases, founded in 2017 and headquartered in Planegg, Germany. The company is at Series A stage with a lean pipeline of two programs targeting retinal dystrophy and retinitis pigmentosa.
Profile data last refreshed 21h ago · AI intelligence enriched 1w ago
Funding Stage
SERIES A
Open Jobs
0
About VeonGen Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow VeonGen Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from VeonGen Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
VG901
Retinitis PigmentosaClinical Trials (1)
NCT06291935Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
Phase 1Help build intelligence for VeonGen Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.